Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
16. September 2024 08:00 ET
|
Allarity Therapeutics, Inc.
- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR),...
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
25. Juni 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
27. März 2024 08:30 ET
|
Allarity Therapeutics, Inc.
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of...
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
05. Dezember 2023 07:30 ET
|
Allarity Therapeutics, Inc.
All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response Early data follows Phase 2 dose optimization...
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
30. August 2023 16:05 ET
|
Allarity Therapeutics, Inc.
- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to...
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
31. Juli 2023 06:00 ET
|
Allarity Therapeutics, Inc.
BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage...
Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies
21. Februar 2023 08:30 ET
|
Processa Pharmaceuticals, Inc.
Our Next Generation Chemotherapies (NGCs) are cancer treatments where the metabolism and/or distribution of an FDA-approved drug has been altered to provide potentially safer and more effective...
Oncology Biosimilar Market Size is projected to reach USD 15.62 billion by 2031, growing at a CAGR of 20.5%: Straits Research
23. November 2022 10:25 ET
|
Straits Research
New York, United States, Nov. 23, 2022 (GLOBE NEWSWIRE) -- A biosimilar is a generic version of a well-known biologic drug. Biologic drugs are medicines made from living things like cells, tissues,...
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal
24. Juni 2022 09:00 ET
|
BriaCell Therapeutics Corp.
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism of action,...
Allarity Therapeutics Provides Update on Dovitinib Program
15. März 2022 08:32 ET
|
Allarity Therapeutics, Inc.
FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...